Media

As seen in The Australian, Dr Megan Baldwin joins the Racura board as Non-Executive Director. Dr Baldwin is a seasoned biotech executive with more than 25 years of experience. She is the Founder and Chief Innovation Officer at Opthea Limited (ASX:OPT; NASDAQ:OPT), a late-stage biopharmaceutical company developing a novel therapy to address the unmet need…

Proactive reports on Racura’s R&D tax rebate and clinical progress made in FY 2024. Read the full article here.

Conducted in two stages, the Phase 1 clinical trial will examine the safety and tolerability of the reformulated bisantrene, RC220, in particular the drug’s cardioprotective ability when used in combination with doxorubicin, a form of anthracycline commonly used in chemotherapy. The ethics submission is a milestone after a year’s preparation, with the first patient recruitment…

Racura Oncology Ltd (ASX:RAC, OTC:RAONF) has taken another key step toward a Phase 1 trial in solid tumour patients using RC220 bisantrene by submitting an application for an ethics and regulatory package to Bellberry Human Research Ethics Committee (HREC) for approval. Read the full article here. Watch the interview with CEO and MD Dr Daniel Tillett.

Racura CEO Dr Daniel Tillett joins Proactive’s Tylah Tully to discuss the FTO drug discovery program the company has concluded at Monash University’s Fragment Platform (MFP). Watch the full interview below and for the full news report via this link.

CEO and MD Dr Daniel Tillett joined ausbiz post the release of September Quarterly Activity Report, reaffirming the company’s strong funding position, clinical pipeline, and noting changes in the Board and Management team. Watch the full interview via this link.

Racura Oncology joins four other biotech companies to present at HealthInvest 2024, hosted by IR Department, Morgans and Stockhead. At the conference, Racura presented the clinical development history of its lead asset bisantrene, and the pipeline for the coming months to investors, analysts and industry peers in the room. Watch the interview with Dr Peter…

Racura Executive Chair Dr Peter Smith speaks with Proactive about the recent board changes and the company’s clinical pipeline for its lead drug asset, bisantrene. Read the full report here.

Racura Oncology is pleased to release the FY24 annual report. Key highlights include: Read the full report via this link.